Loading organizations...
Key people at California Institute for Biomedical Research.
The California Institute for Biomedical Research is a La Jolla, California-based nonprofit organization that bridges basic biomedical research and clinical drug discovery to develop new therapies for unmet medical needs. Operating as a 501(c)(3) entity, the institute functions as the primary drug discovery and development division of Scripps Research following a strategic affiliation signed in October 2016. The organization translates academic scientific discoveries into potential treatments for conditions such as diabetes, chronic obstructive pulmonary disease, and cancer immune therapies, utilizing initial financial backing provided by Merck. Calibr maintains a self-sustaining operational model guided by a board and advisory team featuring leadership from 5AM Ventures and Harvard University, expanding steadily over its first decade from an initial core team of 10 employees. The California Institute for Biomedical Research was founded in 2012 by Peter G. Schultz.
Key people at California Institute for Biomedical Research.
The California Institute for Biomedical Research (Calibr), now known as Calibr-Skaggs Institute for Innovative Medicines, is an independent nonprofit translational research institute founded in 2012 to accelerate the development of new medicines addressing unmet medical needs.[1][2][3] It operates as the drug discovery and development division of Scripps Research, leveraging a self-sustaining "evergreen" model where revenues from commercial partnerships are reinvested into preclinical and clinical research across diseases like cancer, autoimmunity, infectious diseases, and neurodegeneration.[1][3][4] Calibr bridges basic research to clinic-ready therapeutics, including small molecules, peptides, biotherapeutics, and cell therapies, through collaborations with global researchers and industry partners, fostering innovation in a 50,000-square-foot La Jolla facility housing over 130 scientists.[1][3]
Calibr was established in 2012 by Dr. Peter G. Schultz, a renowned chemist and Institute Director, as an independent nonprofit to translate academic discoveries into viable drugs more efficiently than traditional models.[1][2][4] Schultz, who later became CEO of Scripps Research in 2015, built on prior collaborations, leading to a strategic affiliation in October 2016 where Calibr integrated as Scripps' drug discovery arm.[3][4] This evolution shifted Calibr from standalone operations to a division within the larger Scripps ecosystem, enhancing resources while maintaining its focus on bold, high-impact projects; early milestones included antibody platforms for chronic diseases and cancer immunotherapies.[4]
Calibr rides the wave of translational biomedicine, where AI-driven discovery and precision therapies demand faster bridges from lab to clinic amid rising chronic disease burdens and post-pandemic focus on neglected infections.[3] Its timing aligns with biotech's shift toward nonprofit hybrids, countering Big Pharma's risk aversion by de-risking novel mechanisms—Scripps' 1,100+ patents and 11 FDA-approved drugs underscore this ecosystem influence.[4] Market forces like aging populations and antimicrobial resistance favor Calibr's agile model, which has spun insights into 50+ companies via Scripps, amplifying startup momentum in San Diego's biotech hub.[1][4]
Calibr-Skaggs is poised to expand its pipeline through deeper AI integration and global partnerships, targeting Phase II/III trials in oncology and rare diseases while scaling its evergreen model for sustainability.[3][5] Trends like cell/gene therapies and multi-omics will shape its trajectory, potentially yielding more spinouts amid biotech funding rebounds. Its influence may evolve by setting a blueprint for nonprofit drug engines, reinforcing Scripps' leadership and delivering therapies that outpace for-profit timelines—ultimately proving nonprofits can sustain biomedical acceleration.[1][3]
